wait lead program firm
price month
 close
like demonstr initi efficaci sldb dmd gene
therapi clear mechanist rational well support
becom standard care dmd sustain run rate revenu
anticip clinic differenti time market durabl
among meaning arbit valu among three clinical-
stage dmd gene therapi product expect longer-
term data refin think model assumpt
clear efficaci differenti earli clinic gene therapi updat
assum function level dystrophin express three clinic
player in-lin preclin profil think competit initi profil
efficaci may support nt upsid improv po
data expect howev longer term see potenti
risk share price solid third mover fail produc
differenti clinic data experi delay owe regulatori issu
manufactur timelin
steadi newsflow dmd gene therapi come
month expect updat result srpt gene therapi program later
year top-lin result program
note srpt clinic success view posit
share far rel valuat argument think bar
could elev profil matur initi data produc
dystrophin express ck reduct
initi neutral target price valuat dcf-driven
po dmd gene therapi market share
risk thesi includ clinic regulatori commerci headwind
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
clinic stage biotechnolog compani focus
develop therapi treat duchenn muscular dystrophi
dmd compani lead product candid gene
therapi clinic develop treat dmd
blue sky scenario assum probabl
success dmd gene therapi market
share market share
grey sky scenario reflect stock trade cash
event fail clinic develop
 close
initi coverag neutral rate target price see
reason optim gene therapi dmd clinic develop support
intuit mechan action preclin proof-of-concept clinic
proof-of-concept competitor relat drug rel impli valuat competit
gene therapi program lend support sldb valuat howev lack clinic data
compani third-mov posit dmd gene therapi limit visibl
abil clinic differenti base earli efficaci data lead us conclud
current valuat reason balanc invest risk upsid potenti addit
initi clue competit efficaci profil data first avail
also look confirmatori evid sae observ first-dos
patient manag indic neg differenti ae profil
gene therapi develop dmd mechanist
approach provid patient truncat dystrophin gene treatment dmd
ground clear biolog dmd caus mutat dystrophin gene lead
insuffici level function dystrophin protein truncat dystrophin gene
function associ milder diseas dose vg/kg
demonstr function benefici micro-dystrophin express
wild type level grmd canin model greater human believ
clinic meaning meanwhil initi clinic efficaci srpt micro-dystrophin
gene therapi valid translat preclin express efficaci data
dmd gene therapi rapidli evolv field busi near-term catalyst line-up
expect updat result srpt trial later year assum top-lin result
pfizer program report biopsi data could gather end
data dose cohort solid plan
present initi data although expect data like go report
sooner model gene therapi futur standard care dmd project sgt-
recur sale assum share pend evid potenti
favor neg differenti long-term
credit suiss biotech short-term outlook share price movement
come month like driven competitor clinic trial result
clarifi timelin expect data evidenc longer durat later year like
octob plan present top-lin one-year data think
biopsi data across two dose cohort could present earli
evid initi efficaci safeti profil solid guid
data think interim biopsi updat could avail
credit suiss biotech long-term outlook think long-term valu
variou dmd gene therapi program clinic develop heavili influenc
clinic differenti time market assum largest determin solid
futur valu clinic regulatori timelin progress note
progress and/or setback competitor program could influenc share price
volatil signific degre
credit suiss biotech outlook pure play key biotech market
solid attract lt candid expect interest may pick sgt-
clinic profil develop solid need clarifi freedom use around
vector develop commercial-scal manufactur plan ahead activ
gene therapi mechanist intuit treatment approach
dmd base clear diseas biolog
demonstr micro-dystrophin express wt
grmd canin model improv translat
function benefit meanwhil initi efficaci srpt
valid
dmd gene therapi construct differ therefor clinic
efficaci seen construct gener
micro-dystrophin spectrin-lik
repeat includ srpt micro-dystrophin
exact benefit includ two sr
demonstr clinic
optimist efficaci gene therapi mechanist intuit treatment approach dmd
notion truncat dystrophin function activ well document believ preclin proof-of-concept result sgt-
strongli suggest effect clinic
sae first patient dose spuriou event
wont reoccur addit patient treat fda
appear comfort continu dose patient
even similar event aris appear short cours
steroid eculizumab could resolv inflammatori respons
sae appear relat activ innat
immun system duan fact dont know
exact caus event concern one hypothesi
innat immun respons vector
case addit sae may occur dose patient
potenti dose escal futur dose may
doubl use first patient lastli possibl
eculizumab prednison wont alway enough
mitig immun respons
find sae concern await addit clinic data one plausibl hypothesi respons vector
patient nonambulatori older therefor absolut dose size upper end gene therapi dose
administ date solid decis dose ambulatori patient first go back nonambulatori patient mitig
safeti risk given smaller absolut vector dose
therapi includ sr
respons bind nno sarcolemma nno involv
number muscl activ
atrophi preclin result suggest local nno
unclear signific differ construct
literatur support approach head-to-head
preclin studi perform assess differ
micro-dystrophin construct srpt therapi set high bar
unlik superior efficacy/differenti observ
month year durat claim
construct may cardiac express advantag
current enough inform confid claim one construct superior anoth preclin evid suggest
may advantag transduc heart larg anim model
clinic hold due remov clinic patient sinc remov clinic gene therapydata updat like initi patient fall possibl earli gene therapi treatment sma implic dmd gene therapi dmd gene therapi gene therapi possibl dmd gene charl martineau pm univers toronto
let hear boy dmd gene therapi
intuit mechanist approach promis preclin result imbu
confid therapi biolog activ
addit data need determin sae first patient dose
spuriou event indic system issu
differ construct pfe approach howev
clinic implic chang unclear
dmd market larg enough support multipl player pend data base
model assum come market captur dmd
gene therapi market recur sale
duchenn muscular dystrophi dmd progress muscl wast diseas afflict
patient unit state us annual incid
patient diseas character loss ambul second decad
life inabl perform everyday activ biolog diseas well
character diseas result loss function mutat dystrophin
gene lead insuffici function dystrophin protein product
dmd treatment today gener consist steroid clinic proven delay
loss ambul support care addit srpt exondi approv
us ptc translarna approv europ nich segment
popul none exist therapi convey signific benefit long-term
prognosi poor even current standard care life expect year
age death often result cardiac respiratori failur
dmd us eu inherit patternx-link recessiveag onsetgener yr agegen implicateddystrophin full gene larg fit aav capsid pathologypati dmd neglig product protein dystrophin critic muscl fiber strength/stabl exon popul exon popul exon popul nonsens mutat popul symptomscardiomyopathi respiratori insuffici profound muscl wast weaknessdiseas progressionloss ambul age commonli late teen even treatmentcurr treatment steroid prednison emflaza translarna approv exu patient nonsens mutationsexondi approv us patient amen exon skippingsupport carecommon charl martineau pm univers toronto
solid micro-dystrophin gene therapi develop
treatment dmd therapi util capsid promot deliv
truncat version human dystrophin gene heart skelet muscl therebi
therapi approach
theoret address entir dmd popul compar current approach
avail patient segment specif mutat
believ gene therapi logic treatment approach dmd
well-establish biolog dmd result mutat dystrophin gene
lead insuffici product function dystrophin protein therefor
provid patient copi dystrophin gene micro/mini-dystrophin
gene case dmd gene therapi result function dystrophin
result revers diseas phenotyp
evid truncat dystrophin function dmd gene
largest gene human bodi compris exon result
size constraint aav vector packag capac aav
gene therapi provid full dystrophin gene instead dmd gene
therapi deliv truncat dystrophin gene concept micro-dystrophin
aros discoveri larg delet within dystrophin gene
associ extrem mild case becker muscular dystrophi bmd
appear highli motiv promot treatment dmd evidenc
acceler approv exondi
preclin proof-of-concept system administr result
widespread micro-dystrophin express across target muscl tissu
dystrophin express quadricep heart rel
wt mice figur meanwhil grmd canin dystrophin express
skelet muscl rang vg/kg dose
vg/kg dose figur therapi led function improv
exon therapi potenti address charl martineau pm univers toronto
clinic proof-of-concept competitor present initi result
first four patient dose gene therapi june ck level drop
therapi appear convey function benefit patient
abl ascend stair reciproc day follow treatment someth
unabl two day gene therapi addit video evidenc patient
ascend stair reciproc patient abl run day gene
figur mice three month
micro-dystrophin express canin
figur led function improv canin
current trial trial plan enrol ambulatori
nonambulatori patient across four cohort three dose cohort
untreat control solid expect initi result studi although
think data may present sooner earli sign efficaci perhap
first cohort trial test vg/kg wait period follow
dose first patient within cohort expect initi data like includ
patient first two dose cohort studi sinc sldb vg/kg dose
lower end therapeut efficaci preclin model sarepta earli clinic result
suggest translat efficaci move dmd preclin model clinic
model may appropri expect report believ dose
resum sinc clinic hold expect addit patient enrol soon
offset enthusiasm seriou advers event first
patient dose drug sever day receiv vg/kg
patient platelet count count drop evid complement
activ patient remain clinic stabl gener asymptomat
event deem unexpect seriou advers reaction susar program
place clinic hold patient fulli recov follow iv steroid limit
cours eculizumab
sae appear relat activ innat immun system duan
howev unclear underli caus whether result
size dose activ construct impur dose
someth els regardless exact caus fda remov clinic hold june
compani expect recomm dose come month studi chang
associ lift clinic hold includ
steroid use requir iv glucocorticoid initi week follow
administr
monitor enhanc monitor measur includ panel complement
time biopsi compani abil obtain biopsi day
trial compani obtain biopsi baselin one year
one time point studi either day
patient popul solid origin strategi first enrol older nonambul
patient studi move forward solid go enrol younger ambul
patient first return older nonambul patient
although resolv novemb compani receiv partial clinic hold
prevent dose patient dose higher compani
plan three dose cohort partial clinic hold requir compani
util singl product lot per patient demonstr
appropri manufactur process place support higher dose
dmd gene therapi durabl respons tbd reason optim exist
date durabl express seen year dog model
compani slide addit muscle-target gene therapi shown
durabl xlmtm dog model bold
long-term durabl mini/micro-dystrophin express human unknown
see reason expect multi-year benefit key determin long-term gene
express turnov rate underli tissu target therapi rel
liver-target gene therapi hemophilia must contend uncertainti
around durabl limit hepatocyt turnov dmd gene therapi target heart
skelet muscl cell cell turnov rel reduc number
cardiomyocyt remain constant human lifespan limit turnov
cell figur birth rate year old birth rate
averag lifespan skelet muscl year healthi patient much
shorter patient dmd howev unlik heart skelet muscl mass increas
throughout childhood given nonintegr natur aav gene therapi possibl
new muscl mass establish follow gene therapi administr may experi
dilut effect function micro-dystrophin final import note
matur dmd patient experienc degre fat fibrot deposit muscl
result repeat damage/repair cycl owe underli diseas could
impact benefit micro-dystrophin and/or therapeut durabl
trial designdesignopen-label cohort dose cohort untreat controlnumb patient total ambulatori vg/kg dose undisclos expect higher trial univ floridapati yr oldinclus criteria establish clinic diagnosi dmd document dystrophin gene mutat predict dmd phenotyp confirm absenc dystrophin determin muscl biopsi ambulatori patient antibodi protocol-specifi threshold adolesc non-ambulatori protocol-specifi criteria children ambulatori protocol-specifi criteria stabl daili dose oral corticosteroid wksexclus criteria cardiac abnorm exposur drug affect dystrophin utrophin express within month prior screeningprimari endpointsafetyselect secondari endpoint chang baselin microdystrophin express muscl biopsi activ treatment group charl martineau pm univers toronto figur heart cell turnoverhealthi patient
higher cell turnov younger patient
figur skelet muscl grow significantli
first year life
sarepta also current develop clinical-stag dmd gene therapi
present promis initi data first four patient dose meanwhil initi result
pfizer program expect within come month
figur comparison clinic program
cell birth rateageendotheli cellsmesenchym muscl mass kg sarepta micro-dystrophin solid possibl double-blind placebo-control cohort copen-label cohort dose cohort untreat controlopen-label dose cohortsnumb cohort ambulatori cohort patient total ambulatori patient total ambulatori vg/kg disclos think higher dose need could vg/kgthe compani disclos dose compar preclin studi think scale vg/kg vg/kgtrial us univ us duke ucla univ utah patient month yr yr oldinclus criteria mutat exon ck elev u/l averag bayley-iii motor assess gross motor defin scale score previou treatment steroid month yr old stabl steroid least wk yr old establish clinic diagnosi dmd document dystrophin gene mutat predict dmd phenotyp confirm absenc dystrophin determin muscl biopsi ambulatori patient antibodi protocol-specifi threshold adolesc non-ambulatori protocol-specifi criteria children ambulatori protocol-specifi criteria stabl daili dose oral corticosteroid wk diagnosi duchenn muscular dystrophi confirm medic histori genet test bodi weight kg receipt glucocorticoid month stabl daili dose least month prior studi entryexclus criteria sign cardiomyopathi includ echocardiogram eject fraction subject antibodi titer cardiac abnorm exposur drug affect dystrophin utrophin express within month prior screen neutral antibodi nab adeno-associ viru serotyp pre-exist anti-dystrophin t-cell respons compromis cardiac function indic left ventricular eject fraction less cardiac mri prior exposur gene therapi agent includ exon-skip missens agentsprimari endpointsafetysafetysafetyselect secondari endpoint chang micro-dystrophin express pre vs post treatment decreas ck time test north ambulatori assess time go ascend descend step hand-held dynamometri hhd cardiac mri chang baselin microdystrophin express muscl biopsi activ treatment group month evid mini-dystrophin express distribut assess immunohistochemistri western blot and/or lc-m use upper limb muscl biopsi time frame baselin month year post-treat charl martineau pm univers toronto
therapi produc promis preclin efficaci profil although
micro-dystrophin gene dmd gene largest gene human bodi
compris exon result size constraint aav
vector packag capac aav gene therapi provid
full dystrophin gene differ gene therapi develop elect
include/exclud certain domain base interpret featur
may ultim produc optim clinic respons
concept micro-dystrophin aros discoveri larg delet
within dystrophin gene associ extrem mild case becker
muscular dystrophi england et al construct slight
variat includ actin bind domain hing cysteine-rich
domain preclin data publish present three clinical-stag
program support expect robust dystrophin express earli
figur compani therapi construct slightli differ
promot promot control express therapeut gene often
tissu specif activ certain cell type dmd gene therapi
target skelet heart muscl effect sarepta program
util promot solid construct util promot
public formerli product refer use
promot differ awar two
promot includ cardiac-specif enhanc
promot hand approxim smaller
goncalv et al possibl make attract solid
may save space allow inclus fifth spectrin-lik repeat region
capsid sarepta gene therapi util capsid similar
solid use capsid numer publish
mous studi suggest capsid effect transduc skelet
cardiac muscl tissu publish preclin evid univers
missouri lab dr duan lead scientif advisor solidwhich use
pioneer solid gene therapi program support
effici cardiac gene transduct neonat dog pan
duan et al human gene ther method public lab
suggest cardiac transduct young adult dystroph dog may limit
yue duan et al mol ther base public grant
report updat duan et al appear univers missouri lab
current evalu novel capsid solid micro-
dystrophin gene construct promot next gener gene therapi
unclear signific differ literatur support
approach instanc paper js chamberlain et al found
promot effect promot studi author time support
sarepta decis use promot cassett howev author
subsequ author solid preclin studi use newer promot
sarepta design built optim effort made mendel construct
origin lab nationwid children hospit sarepta indic
preclin work includ evalu larg number possibl combin
manag feel attract efficaci trade-off come inclus
believ support forc gener protect muscl damag
micro-dystrophin includ nno preclin model found nnos-restor
micro-dystrophin contain within spectrin-lik repeat may
effect improv muscl function stabil lai et al
pfizer construct larg similar mendel construct key differ
choic vector vs promot human muscl specif
promot vs cmv patient mendel studi dose either vg/kg
vg/kg local inject bicep treatment fail establish
long-term transgen express like result immun respons four six
patient dose t-cell respons micro-dystrophin
figur preclin data three clinical-stag gene therapi program
referencedosestudi durationefficacyck mdx micegonzalez et al skelet muscl heart expressionstatist signific improvementn/acanin model grmd crudel et al vg/kg vg/kg dog month follow-upn/an/ano evid anti-dystrophin t-cell responsescanin model grmd gonzalez et al vg/kgn/aat higher two dose dystrophin express heart skelet muscl n/an/apfizermdx rat modelbink et al vg/kgbiopsi month month minim effect dose found vg/kgdystrophin posit fiber month month bicepsdystrophin posit fiber month month diaphragmdystrophin posit fiber month month cardiac vg/kgdystrophin posit fiber month month bicepsdystrophin posit fiber month month diaphragmdystrophin posit fiber month month cardiac musclehighli statist signific drop ck level vg/kg doseth protein seen host immun system yet humor respons detect transgen product capsid impact therapeut efficaci test item follow-upsareptamdx mous modelsrpt vg correspond vg correspond vg correspond week note mdx mous model mild phenotyp dystrophin posit fiber greater posit muscl fiber strong heart express diaphragm dystrophin posit fiber vg/kg equival dystrophin express heart rel skelet musclestatist signific improv ck vg dose data provid dose induc anatom lesion muscl administrationnhp safeti studysrpt vg/kgn/an/an/ano abnorm immunolog respons observ deliveri micro-dystrophin antibodi decreas postsepar nhp dose charl martineau pm univers toronto
ideal product profil
ultim matter clinician clinic profil spoke multipl dmd expert
determin ideal product profil dmd gene therapi conclus includ
minimum gene therapi delay loss ambul three
year ambul patient ideal clinician hope therapi move
patient milder becker muscular dystrophy-lik phenotyp said given
lack treatment option delay loss ambul three five year
suffici compel use although suspect price power
treatment would limit
preserv respiratory/cardiac function compel use
nonambulatori patient expert believ gene therapi could strong
appeal patient nonambul preserv remain motor
consist respons patient expert would like see consist
predict respons therapi patient dose rel consist
closer normal micro-dystrophin express better micro-
dystrophin express therefor function benefit like declin
time therefor therapi aim convey close normal micro-
dystrophin express possibl
respiratori failur two lead caus death dmd patient
thought solid pend updat
believ unlik solid top-lin data possibl earlier better
seen sarepta product think sarepta product profil set
high bar dystrophin improv depend quantif
techniqu drop ck level appar motor mileston improv
obviou point differenti solid could demonstr initi updat
higher dystrophin express howev seem somewhat unlik
absenc clariti provid data patient treat higher dose preclin
studi vg/kg dose low dose result dystrophin
express mdx mice expect roughli similar express level seen
patient base saw srpt experi sarepta microdystrophin
program relationship preclin clinic dystrophin express
meanwhil think sae first patient rais studi safeti risk previous
state appear sae may due innat immun system respons
absenc know exact reason immun respons question possibl
addit sae solid potenti increas dose two-fold fourfold
long-term unsur demonstr clearli differenti product
profil main point theoret differenti may improv endur
result local nno sarcolemma preclin evid
bear product construct may clinic attract find
competitor preclin profil compar compel sarepta least
also produc earli demonstr promis preclin profil clinic set
sldb current third-to-market posit necessit perfect execut time
anticip program month behind competitor think could
vulner lt market share basi fall month behind owe
expect strong initi uptak dmd gene therapi greater opportun
competitor provid meaning differenti lt clinic data greater
opportun competitor produc differenti evid lt durabl effect
manufactur could gate step potenti acceler approv
solid clinic trial support gmp product produc compani
bioreactor program clinic util herp viru manufactur
process believ clinical-stag gene therapi compani util though
also develop baculoviru system
think opportun acceler approv path dmd gene therapi highli
probabl could conting manufactur scale-up solid indic
decis build commerci scale product wont made initi data
studi hand base compani timelin commerci buildout
like commenc entir process could take one two year
complet anticip commercial-scal product avail dose
end note avxss technolog transfer took two year util similar
adher cell system sarepta assum month sarepta
expect gene therapi broadli rapidli adopt given high unmet need
see room multipl player absenc clear differenti addit data may
need gener gain full penetr follow popul
nonambulatory/old dmd patient sarepta dose
ambulatori patient trial meanwhil solid plan dose ambulatori
patient first move nonambulatori set believ
unlik nonambulatori dmd patient recov ambul believ
demonstr cardiovascular respiratori benefit compel product use
set
redosing/pati high antibodi sinc pfizer/solid sarepta
util differenti capsid opportun redos anoth construct may
possibl patient requir addit support later life term
restrict patient seek initi dose estim dmd
patient antibodi could prevent dose solid gene
therapi antibodi rate report level
unrel work hemophilia current on-going evalu dose patient
high antibodi titer success set could posit
ramif solid micro-dystrophin loosen inclus criteria
companysystemcommentsolidherp viru suspens systemha potenti produc higher yield scalabl adher cell system process novel fewer compani clinic approach agtc use manufactur adher systemsimilar process avx challeng scale suspens suspens system use multipl gene therapi compani current clinic process scalabl adher charl martineau pm univers toronto
revenu build assum follow
us price million gross million net see launch price
sma meaning comp investor watch
gene therapi market share base fact product
differenti unclear srpt initi result set high efficaci
model plu addit year termin valu patent extend
cs revenu buildmartin summari entpeak shareyr peakgen therapi market patient gene therapi patient gene therapi solid gene entpeak shareyr peakgen therapi market peak growth patient gene therapi patient gene therapi solid gene yr patient perform net entpeak shareyr peakgen therapi market peak growth patient gene therapi patient gene therapi solid gene yr patient perform net charl martineau pm univers toronto
arriv target price use blend valuat approach includ
product-bas dcf dcf
dcf model assum discount rate standard discount rate
early-stag clinic compani fully-dilut share million tax rate
assign five year termin valu micro-dystrophin gene therapi
valu pipelin
detail dcf compon includ follow
second valuat scenario support target reflect
increas revenu off-set decreas decreas
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
adjust base program specif histor probabl success specif
diseas categori standard mind assign follow probabl
success solid pipelin
somewhat higher typic probabl success
phase asset reflect intuit mechanist approach clinic
evid proof-of-concept competitor product off-set sae
identifi first patient dose
equival
compani cash cash equival june project
net cash use oper
blue sky scenario assum probabl success
one-third dmd gene therapi market share one-fourth market share
grey sky scenario reflect stock trade cash event fail
poorli design studi inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
includ
failur develop candid clinic trial demonstr
efficaci favor risk/benefit profil
emerg safeti issu sldb develop
develop risk associ earlier-stag asset
liquidity/fund difficulti develop candid
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
inabl manufactur suffici quantiti pipelin candid
meet clinic commerci demand
difficulti scale gene therapi product meet commerci suppli
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payor-impos access
restrict price reform and/or restrict and/or control specif
access reimburs challeng futur commerci
price challeng sldb product
solid incom statement million except share other- total revenue- cogs- gross profit- oper interest interest incom incom loss incom incom tax expense- net incom net loss attribut net loss prefer unit net loss attribut common dilut net loss/shar basic share dilut share charl martineau pm univers toronto figur balanc sheet
solid balanc sheetal cash ar- inventory- prepaid expens total current fix asset net- goodwill- intang assets- assets- total account accru current portion lt debt- current total current lt debt- lt liabilities- total cstk- prefer stk/other equiti retain total sharehold total liabil sharehold solid flowal incom depreci amortization- stock base comp chang oper assets/li ar- inventory- prepaid expens accru exp net cash use oper purchas fix assets- sale fix assets- purchase/sal invest activity- net cash use invest proce issuanc debt- repay debt- proce issuanc stock- repurchas stock- proce exercis stock options- financ net cash provid financ effect exchang rate- net increas decreas begin end charl martineau pm univers toronto
compani mention price
martin auster certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
